Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Bivalirudin (Angiomax) peptide icon, one bubble per amino acidBivalirudin (Angiomax)20 residuesFPRPGGGGNGDFEEIPEEYLEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Bivalirudin (Angiomax)

ImmuneFDA Approved
25 min half-life·Injection

Also known as: Angiomax, Angiox (EU), BG-8967

Major bleeding cut nearly in half. That's the headline from HORIZONS-AMI, where bivalirudin dropped 30-day major bleeding from 8.3% to 4.9% versus heparin plus GP IIb/IIIa inhibitors in a pooled analysis of 3,602 STEMI patients from HORIZONS-AMI and EUROMAX [1]. Bivalirudin (Angiomax) is a synthetic 20-amino-acid direct thrombin inhibitor, FDA-approved since 2000 for anticoagulation during percutaneous coronary intervention. Its 25-minute half-life means the anticoagulant effect clears fast once the infusion stops. BRIGHT-4 (Lancet 2022, n=6,016) later confirmed that extending the infusion 2 to 4 hours post-PCI eliminates the stent thrombosis concern. Interventional cardiologists reach for it in STEMI, HIT cases, and high-bleeding-risk patients where heparin carries too much baggage.

What Is Bivalirudin (Angiomax)?

Bivalirudin (brand name Angiomax, CAS 128270-60-0) is a synthetic 20-amino-acid peptide and direct thrombin inhibitor used during percutaneous coronary intervention. The HORIZONS-AMI and EUROMAX pooled analysis (n=3,602)[1] showed a 41% reduction in major bleeding and 32% drop in 30-day mortality versus heparin. It binds thrombin at two sites simultaneously: the catalytic active site and exosite-1. That dual-site engagement lets it block both circulating and clot-bound thrombin, something heparin cannot do.

The FDA approved bivalirudin in 2000 for anticoagulation during percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia. Because the peptide never touches platelet factor 4, there is zero HIT risk. Dosing is weight-based: a 0.75 mg/kg IV bolus followed by a continuous infusion at 1.75 mg/kg/h for the duration of the procedure.

Early trials flagged a stent thrombosis signal when the infusion stopped right after PCI. BRIGHT-4 (Lancet 2022, n=6,016)[2] solved that problem. An extended post-PCI infusion at full dose for 2 to 4 hours dropped stent thrombosis to 0.37% versus 1.10% with heparin; major bleeding fell to 0.17% versus 0.80%. A 2024 JACC meta-analysis pooling 6 RCTs and 15,254 STEMI patients confirmed the benefit profile.

Thrombin itself slowly chops bivalirudin apart at the Arg3-Pro4 bond. That proteolytic self-destruction accounts for about 80% of clearance. The remaining 20% goes through the kidneys. With a half-life of roughly 25 minutes, anticoagulant activity fades within 1 to 2 hours of stopping the drip. No reversal agent exists, but the short offset makes one largely unnecessary in most clinical scenarios.

How Bivalirudin (Angiomax) Works

Twenty amino acids, two binding sites, one target. Bivalirudin locks onto thrombin (Factor IIa) at both its catalytic active site and anion-binding exosite-1 at the same time.

The N-terminal D-Phe-Pro-Arg-Pro sequence plugs into the catalytic pocket. The C-terminal hirudin-like dodecapeptide grabs exosite-1, where fibrinogen normally docks. This bivalent grip produces tighter inhibition than active-site-only blockers. It also means bivalirudin reaches clot-bound thrombin trapped in the fibrin mesh; heparin-antithrombin complexes only neutralize circulating thrombin.

The interaction has a built-in off switch. Thrombin cleaves the bivalirudin peptide at the Arg3-Pro4 bond while still bound. That proteolytic cut gradually restores enzymatic function. About 80% of bivalirudin clearance happens this way; the remaining 20% is renal elimination. The result is a half-life of roughly 25 minutes with linear, predictable pharmacokinetics.

By blocking thrombin, bivalirudin shuts down several downstream cascades at once. Fibrinogen stops converting to fibrin. Factor V and Factor VIII activation stalls. Factor XIII can no longer cross-link fibrin strands. Thrombin-driven platelet activation through PAR-1 and PAR-4 receptors is blocked. All of this happens within minutes of the IV bolus, and reverses within 1 to 2 hours after the infusion stops.

Bivalirudin (Angiomax) Benefits

  • Bivalirudin benefits center on safer procedural anticoagulation during coronary interventions, with strong randomized trial backing across STEMI and HIT populations.
  • Major bleeding dropped from 8.3% to 4.9% versus heparin plus GP IIb/IIIa inhibitors across 3,602 STEMI patients in the HORIZONS-AMI and EUROMAX pooled analysis [1].
  • All-cause mortality at 30 days was lower too: 2.1% versus 3.1% in the same trial population. That mortality gap persisted at 3-year follow-up [3].
  • Zero HIT risk. Bivalirudin does not bind platelet factor 4, completely eliminating the immune-mediated thrombocytopenia pathway that makes heparin dangerous for susceptible patients.
  • BRIGHT-4 (n=6,016)[2] settled the stent thrombosis question: extended post-PCI infusion at 1.75 mg/kg/h dropped stent thrombosis to 0.37% versus 1.10% for heparin, while simultaneously reducing major bleeding to 0.17% versus 0.80%.
  • The 25-minute half-life enables faster sheath removal and earlier patient ambulation compared to heparin, particularly at femoral-access sites.
  • Predominantly cleared by proteolytic cleavage rather than hepatic or renal metabolism, making it usable across a wider range of organ function with simple dose adjustments.

Bivalirudin (Angiomax): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 7 key studies·FDA-approved

FDA-approved direct thrombin inhibitor with strong RCT evidence for PCI anticoagulation.

Dosing studied: 0.75 mg/kg IV bolus + 1.75 mg/kg/h procedural infusion; STEMI: extend 2–4h post-PCI at 1.75 mg/kg/h (BRIGHT-4); renal adjustment: 1.0 mg/kg/h (CrCl <30), 0.25 mg/kg/h (dialysis)
Read the evidence (key study, limitations)

Reduces major bleeding vs. heparin + GP IIb/IIIa inhibitors; eliminates HIT risk; BRIGHT-4 (2022) demonstrated extended post-PCI infusion resolves prior stent thrombosis concern. 2024 JACC meta-analysis (n=15,254 STEMI) confirmed benefit. ACC/AHA 2025 ACS Guideline: Class I for HIT, Class IIa for STEMI primary PCI (with extended infusion), Class IIb for NSTEMI PCI.

Key Study

BRIGHT-4 (Lancet 2022, PMID 36351459) + 2024 JACC meta-analysis 6 RCTs n=15,254 STEMI; HORIZONS-AMI (PMID 25572507)

Limitations

Bleeding advantage diminished at high-volume radial-access centers; no reversal agent; cost 20–50× UFH even with generics; IV-only hospital administration: no outpatient use

Community Experience
Moderate
3.5/5
Based on Drugs.com: 7.5/10 (n≈73 patient reviews, post-PCI experience)

Hospital-only IV drug: no self-administration community exists.

Community dosing: 0.75 mg/kg IV bolus + 1.75 mg/kg/h per FDA label; BRIGHT-4 protocol now dominant for STEMI cath labs
Read the reports (what users report 5, common issues 4)

Clinical community (interventional cardiologists, cath lab nursing, pharmacists) sentiment is positive for STEMI/HIT indications since BRIGHT-4. Cost and no-reversal-agent concerns remain common objections. Radial-access operators question incremental benefit for elective PCI.

What users report (5)
  • Eliminates HIT/HITTS risk entirely: no platelet factor 4 binding
  • Lower major bleeding vs. heparin + GP IIb/IIIa: 4.9% vs 8.3% (HORIZONS-AMI)
  • 25-min half-life enables faster sheath removal and earlier ambulation vs. heparin
  • Predictable linear PK: no variability from antithrombin levels or heparin-binding proteins
  • Inhibits both free and clot-bound thrombin (unlike heparin which only neutralizes circulating thrombin)
Common issues (4)
  • Drug cost 20–50× unfractionated heparin despite generic availability; formulary restrictions common
  • No reversal agent: major bleeding managed by stopping infusion and supportive care only
  • Acute stent thrombosis risk if post-PCI extended infusion omitted in STEMI (managed by BRIGHT-4 protocol)
  • IV incompatibility with thrombolytics limits use in pharmacoinvasive STEMI strategies
Science-Only Evidence

Hospital-administered IV anticoagulant with no self-administration community. All dosing data from clinical trials and FDA label. No lay-community protocols or self-experimentation data exist.

Bivalirudin (Angiomax) Dosage Guide

FDA LabelANGIOMAX (bivalirudin) FDA Prescribing Information (2019)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner750 mcg/kgIV bolus, then 1.75 mg/kg/h infusion for the procedure
Moderate750 mcg/kgIV bolus, then 1.75 mg/kg/h infusion for the procedure
Aggressive750 mcg/kgIV bolus, then 1.75 mg/kg/h infusion for the procedure
Note:

This is a hospital-only IV drug. You won't be reconstituting this at home; cath lab pharmacists and nurses handle preparation under physician supervision.

Reconstitution math for the record: each 250 mg vial gets 5 mL of Sterile Water for Injection (SWFI), giving a 50 mg/mL concentrate. That concentrate then gets diluted into 50 mL of D5W or 0.9% NaCl for a final working concentration of 5 mg/mL.

For an 80 kg patient, the bolus is 60 mg (0.75 mg/kg x 80 kg), which works out to 12 mL from the 5 mg/mL solution. The procedural infusion runs at 140 mg/h (1.75 mg/kg/h x 80 kg), so 28 mL/h from the same bag.

The non-obvious thing most clinicians miss early on: a subtherapeutic ACT at the 5-minute check almost always traces back to a weight calculation error. Recheck actual body weight before giving the supplemental 0.3 mg/kg bolus. Estimated weights in emergency STEMI settings cause real dosing errors.

Cycling

Bivalirudin is used acutely during percutaneous coronary intervention and is not cycled. It is administered as a single-session IV bolus plus continuous infusion lasting the duration of the procedure (typically 30-90 minutes) with optional post-PCI infusion extension of up to 4 hours for STEMI patients.

Calculate your Bivalirudin (Angiomax) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Bivalirudin (Angiomax) Protocols by Goal

intermediateFDA LabelProcedure duration only (typically 30–90 minutes)
IV Bolus
Wk Single procedural event
0.75 mg/kg IV · Single bolus · Intravenous
Procedural Continuous Infusion
Wk Procedure duration (typically 30–90 min)
1.75 mg/kg/h · Continuous IV infusion · Intravenous

Expected: ACT >225 sec throughout PCI; reduced major bleeding vs. heparin + GP IIb/IIIa; effective anticoagulation without HIT risk

Monitor: ACT at 5 min post-bolus; supplemental bolus if subtherapeutic; renal function confirmed pre-procedure

How to Inject Bivalirudin (Angiomax)

  1. 1
    Confirm patient weight in kilograms

    All dosing is weight-based. A miscalculated weight is the leading cause of subtherapeutic ACT.

  2. 2
    Step 2

    Reconstitute one 250 mg vial with 5 mL Sterile Water for Injection. Gently swirl until dissolved (50 mg/mL concentrate).

  3. 3
    Step 3

    Withdraw the required volume and dilute in 50 mL of D5W or 0.9% sodium chloride to achieve a 5 mg/mL working solution.

  4. 4
    Step 4

    Administer the IV bolus: 0.75 mg/kg injected over 3 to 5 seconds. For an 80 kg patient, that's 60 mg, or 12 mL from the 5 mg/mL solution.

  5. 5
    Immediately start the continuous infusion at 1.75 mg/kg/h

    For 80 kg: 140 mg/h, which is 28 mL/h at 5 mg/mL concentration.

  6. 6
    Step 6

    At 5 minutes post-bolus, check the activated clotting time (ACT). Target is above 225 seconds. If below 225 seconds, give a supplemental 0.3 mg/kg bolus (24 mg for an 80 kg patient, or 4.8 mL).

  7. 7
    Step 7

    Continue the infusion for the duration of the PCI procedure (typically 30 to 90 minutes).

  8. 8
    Step 8

    For STEMI patients: extend the infusion at the full 1.75 mg/kg/h rate for 2 to 4 hours after the procedure ends (BRIGHT-4 protocol).

  9. 9
    Step 9

    Renal dose adjustments: reduce infusion to 1.0 mg/kg/h for CrCl below 30 mL/min; reduce to 0.25 mg/kg/h for dialysis patients. The bolus dose stays at 0.75 mg/kg regardless of renal function.

  10. 10
    Step 10

    Sheath removal: wait until ACT falls below 175 seconds after stopping the infusion.

  11. 11
    Step 11

    Store reconstituted solution at 2 to 8 degrees Celsius; stable for 24 hours. Diluted solution is stable at room temperature for 24 hours. Do not freeze.

Bivalirudin (Angiomax) Stacking Protocols

Works With

Aspirin

DAPT is standard of care alongside bivalirudin for all PCI. Aspirin cyclooxygenase inhibition complements direct thrombin inhibition. Not a peptide but mandatory co-administration.

81–325 mg loading dose pre-PCI; 81 mg/day indefinite maintenance

Ticagrelor

Preferred P2Y12 inhibitor with bivalirudin in STEMI per BRIGHT-4 protocol and PLATO evidence. Reversible binding and faster onset/offset preferred in acute settings vs. clopidogrel.

180 mg loading dose pre-PCI; 90 mg twice daily maintenance

Clopidogrel

Alternative P2Y12 inhibitor when ticagrelor or prasugrel are contraindicated (prior hemorrhagic stroke, high cost, drug interactions, age >75 in STEMI).

300–600 mg loading dose; 75 mg/day maintenance

Avoid

Unfractionated heparin (concurrent)

Concurrent administration markedly increases major bleeding risk. Do not give UFH with bivalirudin. Note: prior UFH administered en route for STEMI (pre-hospital) is NOT a contraindication to initiating bivalirudin upon cath lab arrival: sequential use per EUROMAX is acceptable.

Do not combine
Thrombolytics (alteplase, reteplase, tenecteplase, streptokinase)

Markedly increased hemorrhagic risk and confirmed IV incompatibility. Do not mix in same IV line. Pharmacoinvasive STEMI strategies (thrombolytic → transfer for PCI) typically require a bivalirudin hold period.

Do not combine
GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)

Planned concurrent use negates bivalirudin's bleeding benefit and is not supported by trial data. Bail-out use is acceptable clinically (BRIGHT-4 allowed it) but the bail-out subgroup showed equivalent, not superior, outcomes vs. heparin. Avoid planned combination.

Enoxaparin / Low Molecular Weight Heparins (concurrent)

Concurrent anticoagulant use increases bleeding risk without therapeutic benefit. If transitioning from pre-hospital LMWH (NSTEMI), bivalirudin bolus timing must account for timing and dose of last LMWH administration.

Estimated Cost

Brand Price
Angiomax (Pfizer/The Medicines Company): largely displaced by generics; branded product not typically on current hospital formularies
Generic / Research
Multiple generics available: Sandoz (authorized generic, first to market), Hospira/Pfizer, Mylan/Viatris, Meitheal. Hospital acquisition cost: ~$143–418 per 250 mg vial / ~$143–214 per PCI case (generic era). Retail (Drugs.com): ~$311–420 per vial. Compare: UFH per PCI case ~$4–10.
Compounded
Not applicable: pharmaceutical-grade IV product; compounding not part of clinical use pathway

Pricing updated 2026-04-09

Bivalirudin (Angiomax) Side Effects

Bleeding is the primary safety concern. Major bleeding events occur in 1.4% to 3.8% of patients across clinical trial populations, including retroperitoneal hemorrhage, intracranial hemorrhage, pulmonary hemorrhage, and cardiac tamponade. Post-marketing surveillance has identified rare fatal hemorrhages and anaphylaxis cases. No approved reversal agent exists. If a patient starts bleeding during the infusion, the only option is stopping the drug and waiting; coagulation normalizes within 1 to 2 hours in patients with normal renal function. For dialysis patients (half-life 3.5 hours), hemodialysis can actively remove it.

Acute stent thrombosis was a legitimate concern in early trials. When the infusion stopped immediately after PCI, stent thrombosis rates within 24 hours exceeded heparin. BRIGHT-4 resolved this by showing that a 2 to 4 hour extended full-dose infusion (1.75 mg/kg/h) eliminated the excess risk. Omitting that extended infusion in STEMI patients is the most preventable adverse outcome with this drug.

Back pain affects up to 42% of patients in clinical trials. That number sounds alarming until you learn the cause: catheterization table positioning during prolonged procedures, not a pharmacologic effect of the drug itself. Nausea occurs in roughly 14% of patients. Headache and vomiting are also reported.

Hypotension can occur, particularly in the acute STEMI population where hemodynamic instability is common regardless of anticoagulant choice. Cardiac tamponade and cardiogenic shock have been reported as serious adverse events, though these are procedural complications rather than drug-specific effects.

Thrombocytopenia has been reported rarely. INR elevation can occur when transitioning to warfarin, not because of a true coagulation change, but because bivalirudin interferes with the PT assay reagent. Ecarin clotting time or dilute thrombin time should be used if accurate DTI monitoring is needed.

Anaphylaxis is rare but documented in post-marketing reports. Any patient with prior hypersensitivity to bivalirudin or hirudin-derived compounds should not receive it.

Contraindications include active major bleeding, severe uncontrolled hypertension, subacute bacterial endocarditis, and severe hepatic impairment with coagulopathy. Bivalirudin is FDA Pregnancy Category B; animal studies showed no harm, but human data is limited. Whether the drug enters breast milk is unknown.

Common Issues & Solutions

Subtherapeutic ACT at 5-min check (<225 sec): administer supplemental 0.3 mg/kg IV bolus; recheck ACT. Weight miscalculation is the most common root cause: verify actual body weight used for dose.

Acute stent thrombosis post-STEMI PCI: most often due to omission of extended post-PCI infusion. Ensure BRIGHT-4 protocol is applied (2–4h full-dose 1.75 mg/kg/h after procedure); cannot be corrected retroactively.

Major bleeding during infusion: stop infusion immediately: no reversal agent exists. Coagulation normalizes within 1–2h (normal renal function) or via hemodialysis (dialysis patients). Initiate standard resuscitative and hemostatic supportive care.

Unexpected INR elevation post-procedure: bivalirudin artifactually elevates INR by inhibiting thrombin in the PT assay reagent. Use ecarin clotting time (ECT) or dilute thrombin time (dTT) if direct thrombin inhibitor plasma level assessment is needed.

Renal status unknown pre-procedure (emergency PCI): use standard dose (1.75 mg/kg/h); obtain stat creatinine; adjust retrospectively if severe impairment identified. Post-procedure monitoring for bleeding must be extended in any case of suspected renal impairment.

Ask AI about this page

Ask AI for a second opinion on Bivalirudin (Angiomax) dosing and side effects

Contraindications

  • Active major bleeding or clinically significant hemorrhage
  • Known hypersensitivity to bivalirudin or any excipient in the formulation
  • Severe uncontrolled hypertension (increased intracranial hemorrhage risk)
  • Subacute bacterial endocarditis
  • Severe hepatic impairment with coagulopathy (limited clinical data)
  • Pregnancy: FDA Category B; use only if potential benefit justifies risk
  • Breastfeeding: unknown whether bivalirudin is excreted in human milk; use with caution in nursing mothers

Drug Interactions

  • Concomitant use with other anticoagulants (warfarin, heparin, enoxaparin, DOACs) significantly increases bleeding risk
  • Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) increase hemorrhage risk when used concurrently
  • Thrombolytic agents (alteplase, reteplase, streptokinase) markedly increase bleeding risk and are IV-incompatible
  • Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) have additive bleeding risk: used together in PCI per guidelines but requires close monitoring
  • NSAIDs and SSRIs may further increase bleeding tendency when used during bivalirudin anticoagulation
  • Concurrent anticoagulant use increases bleeding risk without therapeutic benefit. If transitioning from pre-hospital LMWH (NSTEMI), bivalirudin bolus timing must account for timing and dose of last LMWH administration.

Product Quality

Recommended Monitoring

TestWhenTarget
Activated Clotting Time (ACT)5 minutes after initial IV bolus; periodically during prolonged procedures (>60 min)>225 sec during PCI; <175 sec before sheath removal
Serum Creatinine / eGFR (CrCl)Pre-procedure (routine pre-cath laboratory evaluation)Baseline; guides dose calculation: no target, only dose adjustment thresholds
Complete Blood Count (CBC)Pre-procedure baseline; post-procedure if clinically significant bleeding suspectedBaseline: watch for Hgb drop >2 g/dL or platelet fall post-procedure
Ecarin Clotting Time (ECT) or Dilute Thrombin Time (dTT)If direct thrombin inhibitor plasma level monitoring specifically required (unusual circumstance)Context-dependent; correlates linearly with bivalirudin plasma concentration
Activated Clotting Time (ACT)

Confirms therapeutic anticoagulation; determines need for supplemental bolus; guides sheath removal timing

Serum Creatinine / eGFR (CrCl)

Required for infusion rate dose adjustment: CrCl <30 → 1.0 mg/kg/h; dialysis → 0.25 mg/kg/h

Complete Blood Count (CBC)

Baseline hemoglobin and platelet count; identifies bleeding-related anemia; rule out thrombocytopenia

Ecarin Clotting Time (ECT) or Dilute Thrombin Time (dTT)

INR and aPTT are unreliable for bivalirudin therapeutic monitoring; ECT and dTT are DTI-specific assays

Bivalirudin (Angiomax) Before and After

0-5 minutes

Immediate anticoagulant effect upon IV bolus injection. ACT should be checked at 5 minutes to confirm therapeutic anticoagulation (target ACT >225 seconds).

5-60 minutes

Stable steady-state anticoagulation maintained by continuous infusion at 1.75 mg/kg/h during the PCI procedure. Therapeutic ACT levels sustained throughout.

1-4 hours post-PCI

Extended infusion period for STEMI patients to prevent acute stent thrombosis. Continued anticoagulation monitoring. Sheath removal can be considered once ACT falls below 175 seconds.

25-60 minutes post-cessation

Rapid offset of anticoagulant effect due to short half-life (~25 min). Coagulation parameters return to baseline within 1-2 hours of stopping infusion in patients with normal renal function.

What to Expect

0 to 5 minutes (bolus phase): Anticoagulant effect begins immediately at end of the IV bolus. Therapeutic plasma concentration lands within 2 minutes. The 5-minute ACT check should read above 225 seconds in most patients. Roughly 15 to 25% of cases need a supplemental 0.3 mg/kg bolus per institutional experience data. Transient hypotension can occur. No patient self-reports exist for this drug.

5 to 90 minutes (procedural infusion): Stable anticoagulation at therapeutic ACT levels, maintained by the continuous 1.75 mg/kg/h drip. Clinical trial data confirms procedural success rates equivalent to heparin. Back pain affects up to 42% of patients during this window; it's a positioning issue, not a drug effect. Nausea occurs in about 14%.

1 to 4 hours post-PCI (STEMI extended infusion): This is the window that matters for stent thrombosis prevention. BRIGHT-4 tracked the numbers: stent thrombosis 0.37% with bivalirudin versus 1.10% with heparin; major bleeding 0.17% versus 0.80%. Sheath removal is held until ACT drops below 175 seconds. Access site hematoma monitoring is standard during this phase, especially with femoral access.

25 to 120 minutes post-cessation: The 25-minute half-life means anticoagulant effect fades quickly once the infusion stops. Coagulation parameters return to baseline within 1 to 2 hours for patients with normal kidneys. That rapid offset is why bivalirudin allows earlier ambulation compared to heparin. No drug-specific adverse effects during this offset period; the only pharmacologic concern is transient rebound thrombin activity, which the BRIGHT-4 extended infusion protocol covers.

Detailed Timeline: Science vs Community

0–5 minutes (bolus phase)
Science

Immediate anticoagulation onset at end of IV bolus; ACT should reach >225 sec at 5-min check in most patients. Therapeutic plasma concentration achieved within 2 minutes.

Community

Cath lab experience: 5-min ACT check is standard workflow; supplemental bolus needed in ~15–25% of cases per institutional data. No self-report data exists.

5–90 minutes (procedural infusion)
Science

Stable therapeutic ACT (>225 sec) maintained by continuous 1.75 mg/kg/h infusion. Clinical trial data confirms procedural success rates equivalent to heparin.

Community

Clinical: back pain reported in up to 42% of patients: primarily catheterization positioning, not a pharmacologic drug effect.

1–4 hours post-PCI (STEMI extended infusion)
Science

Extended 1.75 mg/kg/h infusion covers peak acute stent thrombosis risk window. BRIGHT-4: stent thrombosis 0.37% (bivalirudin) vs 1.10% (heparin); major bleeding 0.17% vs 0.80%.

Community

CCU/nursing: sheath removal held until ACT <175 sec; access site hematoma monitoring standard during this window.

25–120 minutes post-cessation
Science

Anticoagulant effect decays with ~25-min half-life; coagulation parameters normalize within 1–2h in normal renal function. No reversal agent required in most cases.

Community

Clinical: enables earlier ambulation and sheath removal vs. heparin; particularly valued in radial-access center protocols where bleeding risk is already low.

Pharmacokinetics

Half-Life
25min
Bioavailability
100% (intravenous administration)
Tmax
Immediate (end of IV bolus injection)
Data Confidence
high

Source: FDA-approved Angiomax prescribing information; 25 minutes in PCI patients with normal renal function

Pharmacokinetics: Active Dose Over Time

t½ = 25 minutes (normal renal function); 34-57 minutes (moderate-severe renal impairment); 3.5 hours (dialysis patients)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
20
Sequence
FPRPGGGGNGDFEEIPEEYL
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Bivalirudin (Angiomax)

  • Patients undergoing percutaneous coronary intervention (PCI)
  • Patients with heparin-induced thrombocytopenia (HIT) or HITTS requiring anticoagulation
  • STEMI patients undergoing primary PCI
  • Patients with acute coronary syndromes requiring catheterization laboratory anticoagulation
  • Patients at high bleeding risk who need procedural anticoagulation (in STEMI PCI, the benefit was not larger than at low bleeding risk; PMID 42663356)

Related Peptides

What Changed for Bivalirudin (Angiomax)

  1. Evidence

    Bivalirudin's edge over heparin in STEMI was not larger at high bleeding risk, per a prespecified BRIGHT-4 analysis in JACC, Aug 28, 2026.

    What this does not mean: It does not show bivalirudin fails at high bleeding risk. Absolute reductions were similar (1.1 vs 1.5 points), and the authors concluded the benefit applied to both groups.

    Source: Journal of the American College of Cardiology 2026, BRIGHT-4 by baseline bleeding risk (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 8, 20268 Citations

References

  1. [1]HORIZONS-AMI: Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  2. [2]Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial (Lancet 2022) (opens in a new tab)(n=6,016)PubMed (opens in a new tab)PubMed
  3. [3]Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in STEMI patients undergoing angioplasty (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  4. [4]FDA NDA 020873
  5. [5]BRIGHT-4: Bivalirudin versus heparin in low and non-low bleeding risk patients undergoing primary PCI for STEMI: the BRIGHT-4 trial (Qiu et al., J Am Coll Cardiol 2026) (opens in a new tab)(n=6,016)PubMed (opens in a new tab)Clinical Trial

Related Tools

Storage & Stability

Before Reconstitution
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C. Protect from light.
After Reconstitution
Reconstituted solution stable at 2-8°C for up to 24 hours. Diluted solution (0.5-5 mg/mL) stable at room temperature for up to 24 hours. Do not freeze.
Temperature
20-25°C (lyophilized); 2-8°C (reconstituted)

Frequently Asked Questions

Predictable pharmacokinetics (no heparin-binding protein variability), lower major bleeding rates vs. heparin plus GP IIb/IIIa inhibitors (HORIZONS-AMI), and complete elimination of HIT risk; bivalirudin doesn't bind platelet factor 4. Its rapid ~25-minute offset also allows faster post-procedure recovery.

No approved reversal agent exists. The primary strategy is stopping the infusion; anticoagulant effect decays within 1–2 hours in patients with normal renal function. For dialysis patients (half-life 3.5 hours), hemodialysis can actively remove it. Supportive care (blood products, surgical hemostasis) is used for major bleeding.

Early trials found an increased rate of acute stent thrombosis when the infusion stopped immediately after PCI. BRIGHT-4 (Lancet 2022, PMID 36351459) showed a high-dose 2–4 hour post-procedural infusion at 1.75 mg/kg/h eliminated the stent thrombosis disadvantage vs. heparin while preserving the bleeding benefit.

Strongest benefit in: STEMI patients undergoing primary PCI with extended infusion (BRIGHT-4) and patients with known or suspected HIT. High bleeding risk did not mean a bigger benefit. In a prespecified BRIGHT-4 analysis (PMID 42663356), 30-day death or major bleeding at low bleeding risk was 1.4% on bivalirudin vs 2.9% on heparin (HR 0.49). At higher bleeding risk it was 8.1% vs 9.2% (HR 0.88, not significant). Absolute reductions were similar, and the authors concluded the benefit applied to both groups. For elective PCI in stable patients, benefit vs. unfractionated heparin monotherapy is less clear. ACC/AHA guidelines list it as Class I for HIT and Class IIa for STEMI PCI.

ACT is a point-of-care test measuring how long blood takes to clot, providing real-time anticoagulation monitoring. The target is >225 seconds. If below 225 seconds at 5 minutes, an additional 0.3 mg/kg bolus is indicated. Unlike heparin, bivalirudin's ACT response is highly predictable, so the 5-minute check is a confirmation step rather than a titration decision.